Sacromeric proteins directed PROTACs as a personalized approach in Hypertrophic cardiomyopathy
Description of the granted funding
Our research aims to prevent the development of Hypertrophic Cardiomyopathy (HCM), a heart condition, in patients with mutations in the TRIM63 gene. Our project has three main goals: -Creating a Heart-on-a-Chip Model: We will develop a miniature, lab-grown heart model using patient-derived stem cells. This model will help us study the disease and test potential treatments in a controlled environment. -Designing Targeted Treatments: We plan to create specialized molecules called PROTACs that can remove the harmful proteins from heart cells. This innovative approach uses the body's natural system to eliminate disease-causing proteins. -Testing the Treatments: We will test these PROTACs in our heart-on-a-chip model to see if they can reduce or reverse the heart damage caused by the disease. This project involves collaboration between international laboratories, combining advanced techniques in computer modeling, chemistry, and tissue engineering.
Show moreStarting year
2025
End year
2028
Granted funding
Funder
Research Council of Finland
Funding instrument
International joint call
Other information
Funding decision number
367827
Fields of science
Pharmacy
Research fields
Farmasia